| Literature DB >> 35629241 |
Chung-Lin Lee1,2,3,4,5, Shan-Miao Lin1, Ming-Ren Chen1, Chih-Kuang Chuang6,7, Yu-Min Syu1, Huei-Ching Chiu1, Ru-Yi Tu6, Yun-Ting Lo3, Ya-Hui Chang1,3, Hsiang-Yu Lin1,3,4,5,6,8, Shuan-Pei Lin1,3,4,6,9.
Abstract
Williams syndrome (WS) is a rare genetic disorder caused by the microdeletion of chromosome 7q11.23. Cardiovascular defects (CVDs) are the leading causes of morbidity and mortality in patients with WS. The most common CVD in patients with WS is supravalvular aortic stenosis (SVAS), which recovers spontaneously similar to branch pulmonary stenosis (PS). Recently, conventional beliefs, such as SVAS improving rather than worsening in WS, have been challenged. This study thoroughly reviews the medical records of 30 patients with a molecular diagnosis of WS. We followed up these patients at Taipei MacKay Memorial Hospital from January 1999 to December 2021. The long-term outcomes of cardiovascular lesions as well as the change in peak pressure gradient in obstructive cardiovascular lesions over time were studied. Among these 30 patients, the most common cardiovascular lesion was SVAS (50.0%), followed by branch PS (36.7%). During the follow-up period, severe SVAS was aggravated (p = 0.021). The peak pressure gradient decreased from 38.4 to 25.3 mmHg (p = 0.001) in patients with branch PS. Among patients with WS, those with severe SVAS deteriorated over time, whereas those with branch PS improved on their own. In patients with WS who presented with branch PS, no disease-specific intervention was needed.Entities:
Keywords: Taiwan; Williams syndrome; branch pulmonary stenosis; cardiovascular defect; supravalvular aortic stenosis
Year: 2022 PMID: 35629241 PMCID: PMC9146911 DOI: 10.3390/jpm12050817
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Number and percentage of cardiovascular lesions in Williams syndrome.
| Cardiovascular Lesions | Number of Patients (%) ( |
|---|---|
| Supravalvular AS | 15 (50.0%) |
| Branch PS | 11 (36.7%) |
| MR | 10 (33.3%) |
| Mitral valve prolapse | 9 (30.0%) |
| TR | 7 (23.3%) |
| ASD | 7 (23.3%) |
| PLSVC | 3 (10.0%) |
| Right pulmonary artery stenosis | 3 (10.0%) |
| Tricuspid valve prolapse | 2 (6.7%) |
| Increased AsAo | 2 (6.7%) |
| Supravalvular pulmonary stenosis | 1 (3.3%) |
| VSD | 1 (3.3%) |
| Small AsAo | 1 (3.3%) |
| Small DsAo | 1 (3.3%) |
| MS | 1 (3.3%) |
| Dilated Ao root | 1 (3.3%) |
Abbreviations: Ao, aortic; AS, aortic stenosis; AsAo, ascending aorta; ASD, atrial septal defect; DsAo, descending aorta; MR, mitral regurgitation; MS, mitral stenosis; PLSVC, persistent left superior vena cava; PS, pulmonary stenosis; TR, tricuspid regurgitation; VSD, ventricular septal defect.
Severity groups of SVAS and branch PS.
| Cardiovascular Lesions | Mild | Moderate | Severe |
|---|---|---|---|
| SVAS | 7/15 (46.6%) | 4/15 (26.7%) | 4/15 (26.7%) |
| Branch PS | 3/11 (27.2%) | 4/11 (36.4%) | 4/11 (36.4%) |
Abbreviations: SVAS, supravalvular aortic stenosis; PS, pulmonary stenosis.
The baseline characteristics and comorbidities in SVAS.
| Patient Number | Gender | Age at First Echocardiography (Year-Old) | Age at Last Echocardiography (Year-Old) | Duration of Follow Up (Years) | Initial Peak PG (mmHg) | Latest Peak PG (mmHg) | Other CVDs |
|---|---|---|---|---|---|---|---|
| 1 | male | 8 | 19.8 | 11.8 | 30 | 32.3 | MVP |
| 2 | male | 11 | 15.8 | 4.8 | 53 | 69 | MR |
| 3 | female | 0 | 10.0 | 10.0 | 51 | 63 | Branch PS, AS, Right pulmonary artery stenosis |
| 4 | male | 19 | 22.4 | 3.4 | 12 | 9 | None |
| 5 | male | 4 | 7.5 | 3.5 | 25.8 | 27.2 | None |
| 6 | female | 38 | 50.8 | 12.8 | 46.3 | 44 | MVP |
| 7 | male | 0 | 1.5 | 1.5 | 59.6 | 69.3 | Branch PS, Right pulmonary artery stenosis |
| 8 | male | 5 | 10.1 | 5.1 | 12 | 9 | None |
| 9 | male | 1 | 6.5 | 5.5 | 58 | 60 | None |
| 10 | male | 1 | 3.5 | 2.5 | 14 | 5 | Increased AsAo |
| 11 | female | 1 | 2.2 | 1.2 | 30 | 31 | Branch PS, MR, TR |
| 12 | male | 0 | 3.0 | 3.0 | 16 | 17 | None |
| 13 | female | 6 | 14.4 | 8.4 | 8 | 8 | MVP, MR |
| 14 | male | 0 | 0.1 | 0.1 | 35.3 | 44 | ASD, PLSVC |
| 15 | male | 0 | 1.0 | 1.0 | 9 | 18 | Branch PS, ASD |
Abbreviations: AsAo, ascending aorta; ASD, atrial septal defect; CVDs, cardiovascular defects; MR, mitral regurgitation; MVP, mitral valve prolapse; PLSVC, persistent left superior vena cava; PS, pulmonary stenosis; SVAS, supravalvular aortic stenosis; TR, tricuspid regurgitation.
The baseline characteristics and comorbidities in branch PS.
| Patient Number | Gender | Age at First Echocardiography (Year) | Age at Last Echocardiography (Year) | Duration of Follow Up (Years) | Initial Peak PG (mmHg) | Latest Peak PG (mmHg) | Other CVDs |
|---|---|---|---|---|---|---|---|
| 1 | female | 0 | 10.0 | 10.0 | 30.9 | 24.4 | SVAS, Right pulmonary artery stenosis |
| 2 | male | 4 | 14.6 | 10.6 | 59 | 39 | MVP |
| 3 | male | 7 | 17.9 | 10.9 | 31 | 26 | TR |
| 4 | male | 0 | 1.5 | 1.5 | 16 | 5 | SVAS, Right pulmonary artery stenosis |
| 5 | female | 2 | 9.5 | 7.5 | 59 | 32 | MVP, MR, TR, Small AsAo, Small DsDo |
| 6 | female | 47 | 52.9 | 5.9 | 51 | 38.4 | MR, TR |
| 7 | female | 1 | 5.5 | 4.5 | 39 | 28 | MVP, MR, PLSVC, TVP, TR, MS |
| 8 | female | 1 | 2.5 | 1.5 | 18 | 8 | Right pulmonary artery stenosis |
| 9 | male | 4 | 15.0 | 11.0 | 18 | 7 | MVP, MR, TR |
| 10 | female | 1 | 2.2 | 1.2 | 39 | 25.9 | SVAS, MR, TR |
| 11 | male | 0 | 1.0 | 1.0 | 61.7 | 45 | SVAS, ASD |
Abbreviations: AsAo, ascending aorta; ASD, atrial septal defect; CVDs, cardiovascular defects; DsAo, descending aorta; MR, mitral regurgitation; MS, mitral stenosis; MVP, mitral valve prolapse; PLSVC, persistent left superior vena cava; PS, pulmonary stenosis; SVAS, supravalvular aortic stenosis; TR, tricuspid regurgitation; TVP, tricuspid valve proplase.
Figure 1Changes in the mean peak velocity of overall (A), mild (B), moderate (C), and severe (D) SVAS at initial echocardiography. The interval was presented as the median value. echoCG, echocardiography; PG, pressure gradient; SVAS, supravalvular aortic stenosis. * p-value was calculated using the Wilcoxon signed-rank test.
Figure 2Changes in the mean peak velocity of overall (A), mild (B), moderate (C), and severe (D) branch PS at the initial echocardiography. The interval was presented as the median value. echoCG, echocardiography; PG, pressure gradient; PS, pulmonary stenosis. * p-value was calculated using the Wilcoxon signed-rank test.
Figure 3Correlation between the initial peak PG and age at first echocardiogram in (A) SVAS, and (B) branch PS. PG, pressure gradient; SVAS, supravalvular aortic stenosis; PS, pulmonary stenosis.
Figure 4Correlation between the last peak PG and (A) age at last echocardiogram, or (B) duration of follow-up in SVAS. PG, pressure gradient; SVAS, supravalvular aortic stenosis.
Figure 5Correlation between the last peak PG and (A) age at last echocardiogram, or (B) duration of follow-up in branch PS. PG, pressure gradient; PS, pulmonary stenosis.